The startup has developed a radioligand therapy platform utilizing Raptamersᵀᴹ, which are peptide-oligonucleotide hybrids, to target and deliver radioactive isotopes directly to cancerous cells. This approach enables more precise treatment options for cancer patients, potentially reducing harm compared to traditional therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer therapies often lack precision, leading to damage of healthy tissues alongside cancerous cells. This can result in significant side effects and limit the effectiveness of treatment, especially in cases where tumors are difficult to reach or have spread throughout the body.
Solution
This startup is developing a radioligand therapy platform that uses Raptamersᵀᴹ (peptide-oligonucleotide hybrids) to selectively target and deliver radioactive isotopes directly to cancer cells. Raptamersᵀᴹ act as targeting moieties, guiding the radioactive payload to the tumor site while minimizing exposure to healthy tissues. This targeted approach aims to improve treatment efficacy and reduce the adverse effects associated with conventional radiation therapy. By precisely delivering radiation to cancerous cells, the platform offers the potential for more effective and less toxic cancer treatments.
Target Audience
The primary target audience includes cancer patients seeking more precise and less toxic treatment options, as well as oncologists and hospitals looking for advanced radiopharmaceutical therapies.
Features
- Raptamerᵀᴹ-based targeting for selective delivery of radioactive isotopes to cancer cells.
- Peptide-oligonucleotide hybrid structure for enhanced targeting and delivery capabilities.
- Platform designed to minimize off-target radiation exposure and reduce side effects.